Intellia CEO on Crispr gene-editing treatment, secondary offering

Intellia Therapeutics president and CEO John Leonard joins 'Closing Bell' to discuss the clinical study of an experimental gene-editing treatment. The company also announced pricing of a secondary offering at $145/share and expects to raise approximately $600 million.